GlassScriptPhysician profile
Justine Bollinger
NPI 1306433602
$3,622.18
in general payments reported to CMS, 2019-2025
22 companies · $1,252 in 2025
The $1,252 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $102 · 2022: $639 · 2023: $595 · 2024: $1,034 · 2025: $1,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,880.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $833.63 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $579.18 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $361.23 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $335.61 | 2023-2025 | Rexulti |
| Abbvie INC. | $279.63 | 2021-2024 | |
| Lilly USA, LLC | $215.58 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $128.80 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Eisai INC. | $121.49 | 2024-2025 | |
| Glaxosmithkline, LLC. | $95.91 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $85.39 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.64 | 2024-2025 | Jardiance |
| Vanda Pharmaceuticals INC. | $71.93 | 2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $68.82 | 2024-2025 | Rexulti |
| Axsome Therapeutics, INC. | $66.37 | 2023-2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $59.07 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $54.23 | 2024-2025 | Veozah |
| Mylan Specialty L.P. | $52.17 | 2022-2024 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $41.27 | 2022-2023 | Eliquis |
| Novartis Pharmaceuticals Corporation | $31.97 | 2023 | |
| Becton, Dickinson and Company | $27.68 | 2023 | Bd Affirm Vpiii Microbial Identification Test |
| Neurocrine Biosciences, INC. | $24.53 | 2023 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $14.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justine Bollinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.